



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
OTC					
US	\$ 686	601	14.0%	14.0%	-
Intl	686	541	26.9%	22.8%	4.1%
WW	1,372	1,142	20.1%	18.2%	1.9%
SKIN HEALTH / BEAUTY					
US	569	572	-0.5%	-0.5%	-
Intl	555	577	-3.8%	-5.5%	1.7%
WW	1,124	1,149	-2.2%	-3.0%	0.8%
ORAL CARE					
US	150	164	-8.4%	-8.4%	-
Intl	248	248	0.1%	-1.8%	1.9%
WW	398	412	-3.3%	-4.5%	1.2%
BABY CARE					
US	95	91	5.2%	5.2%	-
Intl	296	302	-2.0%	-3.1%	1.1%
WW	391	393	-0.3%	-1.2%	0.9%
WOMEN'S HEALTH					
US	3	3	20.1%	20.1%	-
Intl	229	227	0.5%	0.6%	-0.1%
WW	232	230	0.8%	0.8%	0.0%
WOUND CARE / OTHER					
US	122	125	-2.6%	-2.6%	-
Intl	61	64	-5.2%	-9.0%	3.8%
WW	182	189	-3.5%	-4.8%	1.3%
TOTAL CONSUMER HEALTH					
US	1,625	1,556	4.5%	4.5%	-
Intl	2,075	1,958	5.9%	3.7%	2.2%
WW	\$ 3,700	3,514	5.3%	4.1%	1.2%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	NINE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
OTC					
US	\$ 1,960	1,917	2.2%	2.2%	-
Intl	1,894	1,722	10.0%	3.9%	6.1%
WW	3,854	3,639	5.9%	3.0%	2.9%
SKIN HEALTH / BEAUTY					
US	1,862	1,767	5.4%	5.4%	-
Intl	1,595	1,506	5.9%	2.1%	3.8%
WW	3,457	3,273	5.6%	3.9%	1.7%
ORAL CARE					
US	478	510	-6.2%	-6.2%	-
Intl	762	694	9.9%	5.9%	4.0%
WW	1,240	1,204	3.0%	0.8%	2.2%
BABY CARE					
US	288	279	3.3%	3.3%	-
Intl	879	831	5.8%	4.6%	1.2%
WW	1,167	1,110	5.2%	4.3%	0.9%
WOMEN'S HEALTH					
US	9	10	-5.7%	-5.7%	-
Intl	675	654	3.1%	2.3%	0.8%
WW	684	664	3.0%	2.1%	0.9%
WOUND CARE / OTHER					
US	390	370	5.3%	5.3%	-
Intl	186	175	5.8%	0.0%	5.8%
WW	575	545	5.4%	3.6%	1.8%
TOTAL CONSUMER HEALTH					
US	4,987	4,853	2.8%	2.8%	-
Intl	5,991	5,582	7.3%	3.5%	3.8%
WW	\$ 10,978	10,435	5.2%	3.1%	2.1%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					
	THIRD QUARTER					
	2021	2020	% Change			
		Reported	Operational ⁽¹⁾	Currency		
PHARMACEUTICAL SEGMENT ^(2,3)						
IMMUNOLOGY						
US	\$ 2,771	2,558	8.3%	8.3%	-	
Intl	1,480	1,230	20.3%	18.8%	1.5%	
WW	<u>4,250</u>	<u>3,789</u>	12.2%	11.7%	0.5%	
REMICADE						
US	480	634	-24.3%	-24.3%	-	
US Exports ⁽⁴⁾	47	78	-40.2%	-40.2%	-	
Intl	234	209	12.2%	8.1%	4.1%	
WW	<u>761</u>	<u>921</u>	-17.4%	-18.3%	0.9%	
SIMPONI / SIMPONI ARIA						
US	295	312	-5.3%	-5.3%	-	
Intl	276	280	-1.1%	-0.7%	-0.4%	
WW	<u>571</u>	<u>592</u>	-3.3%	-3.1%	-0.2%	
STELARA						
US	1,569	1,313	19.5%	19.5%	-	
Intl	809	634	27.7%	26.3%	1.4%	
WW	<u>2,378</u>	<u>1,947</u>	22.2%	21.7%	0.5%	
TREMFYA						
US	376	222	69.7%	69.7%	-	
Intl	161	105	52.5%	50.5%	2.0%	
WW	<u>537</u>	<u>327</u>	64.1%	63.5%	0.6%	
OTHER IMMUNOLOGY						
US	3	-	*	*	-	
Intl	0	3	*	*	*	
WW	<u>3</u>	<u>3</u>	-26.4%	-27.5%	1.1%	
INFECTIOUS DISEASES						
US	679	413	64.3%	64.3%	-	
Intl	709	451	57.2%	55.6%	1.6%	
WW	<u>1,389</u>	<u>864</u>	60.6%	59.8%	0.8%	
COVID-19 VACCINE						
US	270	-	*	*	-	
Intl	233	-	*	*	-	
WW	<u>502</u>	<u>-</u>	*	*	-	
EDURANT / rilpivirine						
US	12	11	8.4%	8.4%	-	
Intl	247	226	9.7%	8.7%	1.0%	
WW	<u>259</u>	<u>236</u>	9.6%	8.6%	1.0%	
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA						
US	380	379	0.4%	0.4%	-	
Intl	137	147	-7.1%	-8.8%	1.7%	
WW	<u>517</u>	<u>526</u>	-1.7%	-2.2%	0.5%	
OTHER INFECTIOUS DISEASES						
US	18	24	-26.0%	-26.0%	-	
Intl	93	78	18.3%	15.2%	3.1%	
WW	<u>110</u>	<u>102</u>	7.8%	5.4%	2.4%	

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					
	NINE MONTHS					
	2021	2020	% Change			
		Reported	Operational ⁽¹⁾	Currency		
PHARMACEUTICAL SEGMENT ^(2,3)						
IMMUNOLOGY						
US	\$ 7,932	7,330	8.2%	8.2%	-	
Intl	4,464	3,619	23.3%	17.6%	5.7%	
WW	<u>12,395</u>	<u>10,950</u>	13.2%	11.3%	1.9%	
REMICADE						
US	1,508	1,852	-18.6%	-18.6%	-	
US Exports ⁽⁴⁾	197	321	-38.7%	-38.7%	-	
Intl	721	673	7.1%	1.4%	5.7%	
WW	<u>2,426</u>	<u>2,846</u>	-14.8%	-16.1%	1.3%	
SIMPONI / SIMPONI ARIA						
US	840	840	0.0%	0.0%	-	
Intl	877	827	6.1%	2.8%	3.3%	
WW	<u>1,717</u>	<u>1,667</u>	3.0%	1.4%	1.6%	
STELARA						
US	4,396	3,668	19.9%	19.9%	-	
Intl	2,404	1,795	33.9%	27.5%	6.4%	
WW	<u>6,800</u>	<u>5,463</u>	24.5%	22.4%	2.1%	
TREMFYA						
US	975	650	50.1%	50.1%	-	
Intl	459	316	45.4%	38.0%	7.4%	
WW	<u>1,434</u>	<u>965</u>	48.5%	46.1%	2.4%	
OTHER IMMUNOLOGY						
US	15	-	*	*	-	
Intl	3	9	-68.6%	-70.8%	2.2%	
WW	<u>18</u>	<u>9</u>	91.6%	89.5%	2.1%	
INFECTIOUS DISEASES						
US	1,635	1,265	29.2%	29.2%	-	
Intl	1,788	1,397	28.0%	23.2%	4.8%	
WW	<u>3,424</u>	<u>2,662</u>	28.6%	26.1%	2.5%	
COVID-19 VACCINE						
US	421	-	*	*	-	
Intl	346	-	*	*	-	
WW	<u>766</u>	<u>-</u>	*	*	-	
EDURANT / rilpivirine						
US	31	33	-4.8%	-4.8%	-	
Intl	733	684	7.2%	1.7%	5.5%	
WW	<u>764</u>	<u>716</u>	6.7%	1.4%	5.3%	
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA						
US	1,128	1,154	-2.2%	-2.2%	-	
Intl	440	461	-4.6%	-8.6%	4.0%	
WW	<u>1,568</u>	<u>1,615</u>	-2.9%	-4.1%	1.2%	
OTHER INFECTIOUS DISEASES						
US	55	79	-29.6%	-29.6%	-	
Intl	270	252	6.9%	2.6%	4.3%	
WW	<u>325</u>	<u>331</u>	-1.8%	-5.0%	3.2%	

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE					
US	835	759	10.2%	10.2%	-
Intl	854	846	0.8%	-0.5%	1.3%
WW	<u>1,689</u>	<u>1,605</u>	5.3%	4.6%	0.7%
<u>CONCERTA / Methylphenidate</u>					
US	35	43	-19.5%	-19.5%	-
Intl	122	107	14.2%	12.5%	1.7%
WW	<u>157</u>	<u>149</u>	4.5%	3.3%	1.2%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	648	585	11.0%	11.0%	-
Intl	355	341	4.3%	3.2%	1.1%
WW	<u>1,004</u>	<u>926</u>	8.5%	8.1%	0.4%
<u>RISPERDAL CONSTA</u>					
US	71	70	1.3%	1.3%	-
Intl	69	81	-16.7%	-16.0%	-0.7%
WW	<u>140</u>	<u>152</u>	-8.4%	-8.0%	-0.4%
<u>OTHER NEUROSCIENCE</u>					
US	81	60	34.7%	34.7%	-
Intl	307	317	-2.9%	-4.8%	1.9%
WW	<u>388</u>	<u>377</u>	3.1%	1.5%	1.6%
ONCOLOGY					
US	1,525	1,267	20.3%	20.3%	-
Intl	2,140	1,862	14.9%	13.8%	1.1%
WW	<u>3,665</u>	<u>3,129</u>	17.1%	16.5%	0.6%
<u>DARZALEX</u>					
US	841	585	43.7%	43.7%	-
Intl	739	514	43.7%	42.0%	1.7%
WW	<u>1,580</u>	<u>1,099</u>	43.7%	42.9%	0.8%
<u>ERLEADA</u>					
US	214	152	40.5%	40.5%	-
Intl	130	55	*	*	*
WW	<u>344</u>	<u>206</u>	66.7%	65.8%	0.9%
<u>IMBRUVICA</u>					
US	413	450	-8.3%	-8.3%	-
Intl	654	581	12.6%	10.9%	1.7%
WW	<u>1,066</u>	<u>1,031</u>	3.5%	2.5%	1.0%
<u>ZYTIGA / abiraterone acetate</u>					
US	25	58	-57.0%	-57.0%	-
Intl	523	532	-1.8%	-2.1%	0.3%
WW	<u>548</u>	<u>590</u>	-7.2%	-7.5%	0.3%
<u>OTHER ONCOLOGY</u>					
US	32	21	49.6%	49.6%	-
Intl	94	181	-48.0%	-47.2%	-0.8%
WW	<u>126</u>	<u>203</u>	-37.6%	-36.9%	-0.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	NINE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
	2,448	2,285	7.2%	7.2%	-
	2,770	2,565	8.0%	4.1%	3.9%
	<u>5,218</u>	<u>4,850</u>	7.6%	5.5%	2.1%
	117	150	-22.1%	-22.1%	-
	372	319	16.4%	11.6%	4.8%
	<u>489</u>	<u>469</u>	4.1%	0.8%	3.3%
	1,882	1,704	10.4%	10.4%	-
	1,111	983	13.0%	7.6%	5.4%
	<u>2,994</u>	<u>2,688</u>	11.4%	9.4%	2.0%
	210	220	-4.7%	-4.7%	-
	242	254	-5.1%	-8.3%	3.2%
	<u>452</u>	<u>475</u>	-4.9%	-6.6%	1.7%
	239	210	13.9%	13.9%	-
	1,045	1,008	3.7%	1.5%	2.2%
	<u>1,284</u>	<u>1,218</u>	5.5%	3.6%	1.9%
	4,364	3,623	20.4%	20.4%	-
	6,406	5,310	20.6%	15.3%	5.3%
	<u>10,770</u>	<u>8,933</u>	20.6%	17.4%	3.2%
	2,302	1,540	49.5%	49.5%	-
	2,076	1,397	48.6%	42.2%	6.4%
	<u>4,378</u>	<u>2,937</u>	49.1%	46.0%	3.1%
	578	407	41.8%	41.8%	-
	329	112	*	*	*
	<u>907</u>	<u>519</u>	74.7%	72.2%	2.5%
	1,311	1,329	-1.3%	-1.3%	-
	1,996	1,682	18.7%	13.1%	5.6%
	<u>3,307</u>	<u>3,011</u>	9.9%	6.7%	3.2%
	96	284	-66.2%	-66.2%	-
	1,653	1,564	5.7%	0.9%	4.8%
	<u>1,749</u>	<u>1,848</u>	-5.4%	-9.4%	4.0%
	76	63	21.0%	21.0%	-
	352	556	-36.6%	-38.5%	1.9%
	<u>428</u>	<u>619</u>	-30.7%	-32.4%	1.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>PULMONARY HYPERTENSION</u>					
US	610	510	19.7%	19.7%	-
Intl	258	239	7.9%	8.4%	-0.5%
WW	868	749	15.9%	16.1%	-0.2%
<u>OPSUMIT</u>					
US	299	244	22.8%	22.8%	-
Intl	159	148	7.4%	7.8%	-0.4%
WW	458	392	17.0%	17.1%	-0.1%
<u>UPTRAVI</u>					
US	265	226	17.3%	17.3%	-
Intl	44	34	30.4%	28.8%	1.6%
WW	309	260	19.0%	18.8%	0.2%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	47	40	14.4%	14.4%	-
Intl	54	57	-4.4%	-2.1%	-2.3%
WW	101	97	3.4%	4.8%	-1.4%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	800	931	-14.0%	-14.0%	-
Intl	333	351	-5.1%	-8.2%	3.1%
WW	1,133	1,281	-11.5%	-12.4%	0.9%
<u>XARELTO</u>					
US	636	630	0.8%	0.8%	-
Intl	-	-	-	-	-
WW	636	630	0.8%	0.8%	-
<u>INVOKANA / INVOKAMET</u>					
US	66	156	-57.4%	-57.4%	-
Intl	67	68	-1.0%	-4.3%	3.3%
WW	133	224	-40.3%	-41.3%	1.0%
<u>PROCRIT / EPREX</u>					
US	47	69	-30.9%	-30.9%	-
Intl	65	63	3.1%	0.5%	2.6%
WW	112	132	-14.6%	-15.8%	1.2%
<u>OTHER</u>					
US	51	75	-32.6%	-32.6%	-
Intl	200	219	-8.7%	-11.9%	3.2%
WW	251	294	-14.8%	-17.2%	2.4%
<u>TOTAL PHARMACEUTICAL</u>					
US	7,221	6,438	12.2%	12.2%	-
Intl	5,773	4,980	15.9%	14.6%	1.3%
WW	\$ 12,994	\$ 11,418	13.8%	13.2%	0.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	NINE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
	1,778	1,541	15.4%	15.4%	-
	821	742	10.7%	7.3%	3.4%
	2,599	2,283	13.9%	12.7%	1.2%
	861	729	18.2%	18.2%	-
	510	458	11.3%	7.7%	3.6%
	1,371	1,187	15.5%	14.1%	1.4%
	792	692	14.6%	14.6%	-
	135	100	34.6%	27.9%	6.7%
	927	792	17.1%	16.2%	0.9%
	125	121	2.8%	2.8%	-
	176	183	-3.7%	-5.0%	1.3%
	301	304	-1.1%	-1.9%	0.8%
	2,379	2,574	-7.6%	-7.6%	-
	1,007	1,052	-4.2%	-9.3%	5.1%
	3,386	3,625	-6.6%	-8.1%	1.5%
	1,794	1,716	4.5%	4.5%	-
	-	-	-	-	-
	1,794	1,716	4.5%	4.5%	-
	249	405	-38.4%	-38.4%	-
	194	173	11.9%	5.8%	6.1%
	443	578	-23.4%	-25.2%	1.8%
	168	215	-21.7%	-21.7%	-
	198	208	-4.7%	-9.7%	5.0%
	366	423	-13.4%	-15.8%	2.4%
	168	238	-29.3%	-29.3%	-
	615	670	-8.3%	-13.1%	4.8%
	783	908	-13.8%	-17.3%	3.5%
	20,536	18,619	10.3%	10.3%	-
	17,256	14,685	17.5%	12.5%	5.0%
	\$ 37,792	\$ 33,304	13.5%	11.3%	2.2%

MEDICAL DEVICES SEGMENT ⁽²⁾**INTERVENTIONAL SOLUTIONS**

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	THIRD QUARTER				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
US	\$ 444	399	11.1%	11.1%	-
Intl	513	437	17.7%	15.1%	2.6%
WW	957	836	14.5%	13.2%	1.3%
ORTHOPAEDICS					
US	1,249	1,308	-4.5%	-4.5%	-
Intl	843	774	8.8%	6.8%	2.0%
WW	2,093	2,083	0.5%	-0.3%	0.8%
HIPS					
US	210	221	-5.3%	-5.3%	-
Intl	146	124	18.8%	16.0%	2.8%
WW	356	345	3.3%	2.3%	1.0%
KNEES					
US	184	205	-9.8%	-9.8%	-
Intl	131	102	28.1%	25.9%	2.2%
WW	316	308	2.8%	2.1%	0.7%
TRAUMA					
US	455	433	5.3%	5.3%	-
Intl	260	253	2.4%	0.9%	1.5%
WW	715	685	4.2%	3.7%	0.5%
SPINE, SPORTS & OTHER					
US	400	449	-11.1%	-11.1%	-
Intl	306	295	3.5%	1.5%	2.0%
WW	705	745	-5.3%	-6.1%	0.8%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	NINE MONTHS				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
	1,353	1,019	32.7%	32.7%	-
	1,599	1,134	41.1%	34.3%	6.8%
	2,952	2,153	37.1%	33.6%	3.5%
	3,821	3,427	11.5%	11.5%	-
	2,611	2,145	21.7%	15.4%	6.3%
	6,433	5,572	15.4%	13.0%	2.4%
	654	564	15.9%	15.9%	-
	451	344	31.3%	24.1%	7.2%
	1,105	908	21.8%	19.0%	2.8%
	579	527	10.0%	10.0%	-
	403	298	35.4%	28.2%	7.2%
	983	825	19.2%	16.6%	2.6%
	1,352	1,194	13.3%	13.3%	-
	805	698	15.2%	9.5%	5.7%
	2,157	1,892	14.0%	11.9%	2.1%
	1,236	1,142	8.2%	8.2%	-
	952	805	18.2%	12.0%	6.2%
	2,187	1,947	12.3%	9.7%	2.6%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	THIRD QUARTER				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
SURGERY					
US	948	913	3.9%	3.9%	-
Intl	1,457	1,239	17.6%	14.8%	2.8%
WW	<u>2,405</u>	<u>2,152</u>	11.8%	10.2%	1.6%
ADVANCED					
US	440	421	4.6%	4.6%	-
Intl	705	579	21.8%	18.4%	3.4%
WW	<u>1,144</u>	<u>1,000</u>	14.6%	12.6%	2.0%
GENERAL					
US	508	492	3.3%	3.3%	-
Intl	752	660	13.9%	11.7%	2.2%
WW	<u>1,261</u>	<u>1,152</u>	9.4%	8.1%	1.3%
VISION					
US	475	473	0.6%	0.6%	-
Intl	714	608	17.4%	17.4%	0.0%
WW	<u>1,189</u>	<u>1,081</u>	10.1%	10.0%	0.1%
CONTACT LENSES / OTHER					
US	359	375	-4.3%	-4.3%	-
Intl	522	455	14.9%	15.2%	-0.3%
WW	<u>882</u>	<u>830</u>	6.2%	6.4%	-0.2%
SURGICAL					
US	117	98	19.6%	19.6%	-
Intl	191	153	24.7%	23.7%	1.0%
WW	<u>308</u>	<u>251</u>	22.7%	22.1%	0.6%
TOTAL MEDICAL DEVICES					
US	3,117	3,092	0.8%	0.8%	-
Intl	3,527	3,058	15.4%	13.3%	2.1%
WW	<u>\$ 6,644</u>	<u>6,150</u>	8.0%	7.0%	1.0%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	NINE MONTHS				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
	2,881	2,247	28.2%	28.2%	-
	4,418	3,556	24.2%	18.4%	5.8%
	<u>7,299</u>	<u>5,803</u>	25.8%	22.2%	3.6%
	1,304	1,079	20.9%	20.9%	-
	2,126	1,644	29.3%	23.1%	6.2%
	<u>3,430</u>	<u>2,723</u>	26.0%	22.2%	3.8%
	1,577	1,168	35.0%	35.0%	-
	2,292	1,912	19.9%	14.5%	5.4%
	<u>3,869</u>	<u>3,080</u>	25.6%	22.3%	3.3%
	1,414	1,160	21.9%	21.9%	-
	2,103	1,683	25.0%	22.0%	3.0%
	<u>3,517</u>	<u>2,843</u>	23.7%	22.0%	1.7%
	1,082	924	17.0%	17.0%	-
	1,525	1,274	19.8%	17.3%	2.5%
	<u>2,607</u>	<u>2,198</u>	18.6%	17.2%	1.4%
	333	236	41.1%	41.1%	-
	577	409	41.1%	36.7%	4.4%
	<u>910</u>	<u>645</u>	41.1%	38.3%	2.8%
	9,470	7,852	20.6%	20.6%	-
	10,731	8,518	26.0%	20.5%	5.5%
	<u>\$ 20,201</u>	<u>16,370</u>	23.4%	20.5%	2.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales